# EDGAR Filing Document

**Accession Number:** 0001812364
**File Stem:** 0001193125-26-263873
**Filing Date:** 2026-6
**Character Count:** 11063
**Document Hash:** e96383f575981728f05992a9cbe5fa77
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-26-263873.hdr.sgml**: 20260609

**ACCESSION NUMBER**: 0001193125-26-263873

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 10

**CONFORMED PERIOD OF REPORT**: 20260609

**ITEM INFORMATION**: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260609

**DATE AS OF CHANGE**: 20260609

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Relay Therapeutics, Inc.
- **CENTRAL INDEX KEY:** 0001812364
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39385
- **FILM NUMBER:** 261076603

**BUSINESS ADDRESS:**
- **STREET 1:** 60 HAMPSHIRE STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139
- **BUSINESS PHONE:** 617-370-8837

**MAIL ADDRESS:**
- **STREET 1:** 60 HAMPSHIRE STREET
- **CITY:** CAMBRIDGE
- **STATE:** MA
- **ZIP:** 02139

?xml version='1.0' encoding='ASCII'? 8-K

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549**

------

## FORM 8-K

------

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported):** June 09, 2026<br>

------

RELAY THERAPEUTICS, INC.

**(Exact name of Registrant as Specified in Its Charter)**

------

---

| | | |
|:---|:---|:---|
| Delaware | 001-39385 | 47-3923475 |
| **(State or Other Jurisdiction<br>of Incorporation)** | **(Commission File Number)** | **(IRS Employer<br>Identification No.)** |
| 60 Hampshire Street |  |  |
| Cambridge**,** Massachusetts |  | 02139 |
| **(Address of Principal Executive Offices)** |  | **(Zip Code)** |

---

**Registrant's Telephone Number, Including Area Code:** (617) 370-8837<br>

**(Former Name or Former Address, if Changed Since Last Report)**

------

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Securities registered pursuant to Section 12(b) of the Act:**

---

| | | |
|:---|:---|:---|
| **<br>Title of each class** | **Trading<br>Symbol(s)** | **<br>Name of each exchange on which registered** |
| Common Stock, par value $0.001 per share | RLAY | Nasdaq Global Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

## Item 5.03 Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.
On June 9, 2026, Relay Therapeutics, Inc. (the "Company") filed a Certificate of Second Amendment (the "Certificate of Amendment") to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended, with the Secretary of State of the State of Delaware to increase the number of authorized shares of the Company's common stock from 300,000,000 shares to 450,000,000 shares. The increase in the number of authorized shares was approved by the holders of a majority of the votes cast on the matter at the Company's 2026 Annual Meeting of Stockholders (the "Annual Meeting"), as described in Item 5.07 below.

The foregoing description of the Certificate of Amendment does not purport to be complete and is qualified in its entirety by reference to the complete text of the Certificate of Amendment, a copy of which is attached as Exhibit 3.1 to this Current Report on Form 8-K and is incorporated herein by reference.

## Item 5.07 Submission of Matters to a Vote of Security Holders.
On June 9, 2026, the Company held its Annual Meeting to consider and vote on the four proposals set forth below, each of which is described in detail in the Company's Definitive Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on April 28, 2026. The final voting results are set forth below.

**Proposal 1. Election of directors.** 

The Company's stockholders elected each of the following individuals to serve as class III directors for a three-year term ending at the Company's 2029 annual meeting of stockholders and until his or her respective successor is duly elected and qualified, or until his or her earlier death, resignation or removal, with the votes cast as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Name** | &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Withheld** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;Douglas S. Ingram | &nbsp;&nbsp;120859999 | &nbsp;&nbsp;26195825 | &nbsp;&nbsp;24200700 |
| &nbsp;&nbsp;Claire Mazumdar, Ph.D. | &nbsp;&nbsp;122859060 | &nbsp;&nbsp;24196764 | &nbsp;&nbsp;24200700 |

---

**Proposal 2. Non-binding advisory vote on executive compensation.** 

The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers, with the votes cast as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstain** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;143,849,919 | &nbsp;&nbsp;3,154,118 | &nbsp;&nbsp;51,787 | &nbsp;&nbsp;24,200,700 |

---

**Proposal 3. Ratification of appointment of independent registered public accounting firm.** 

The Company's stockholders ratified the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026, with the votes cast as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstain** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;171,030,133 | &nbsp;&nbsp;204,449 | &nbsp;&nbsp;21,942 | &nbsp;&nbsp;0 |

---

**Proposal 4. Approval of amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended**.

The Company's stockholders approved an amendment to the Company's Fourth Amended and Restated Certificate of Incorporation, as amended, to increase the number of authorized shares of common stock from 300,000,000 shares to 450,000,000 shares, with the votes cast as follows:

---

| | | | |
|:---|:---|:---|:---|
| &nbsp;&nbsp;**Votes For** | &nbsp;&nbsp;**Votes Against** | &nbsp;&nbsp;**Abstain** | &nbsp;&nbsp;**Broker Non-Votes** |
| &nbsp;&nbsp;170,323,683 | &nbsp;&nbsp;909,020 | &nbsp;&nbsp;23,821 | &nbsp;&nbsp;0 |

---

No other matters were submitted to or voted on by the Company's stockholders at the Annual Meeting.

------

## Item 9.01 Financial Statements and Exhibits.
(d) Exhibits

---

| | |
|:---|:---|
| 3.1 | [<u>Certificate of Second Amendment of Fourth Amended and Restated Certificate of Incorporation of Relay Therapeutics, Inc., filed with the Secretary of State of the State of Delaware on June 9, 2026.</u>](rlay-ex3_1.htm) |
| 104 | Cover Page Interactive Data File (embedded within Inline XBRL document). |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
|  |  |  | **RELAY THERAPEUTICS, INC.**  |
| Date: | June 9, 2026 | By:  | /s/ Soo-Yeun Lim |
|  |  |  | Soo-Yeun Lim<br>General Counsel |

---

------

## Exhibit 3.1

**Exhibit 3.1**

**CERTIFICATE OF SECOND AMENDMENT** 

**OF**

**FOURTH AMENDED AND RESTATED CERTIFICATE OF INCORPORATION**

**OF**

**RELAY THERAPEUTICS, INC.**

Relay Therapeutics, Inc. (the "<u>Corporation</u>"), a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the "<u>General Corporation Law</u>"),

**DOES HEREBY CERTIFY:**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**1.**That the name of this corporation is Relay Therapeutics, Inc. and that this corporation was originally incorporated pursuant to the General Corporation Law on May 4, 2015 under the name Allostery, Inc.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**2.**That the Board of Directors of the Corporation duly adopted resolutions proposing to amend the Fourth Amended and Restated Certificate of Incorporation, as amended, of the Corporation, declaring said amendment to be advisable and in the best interests of the Corporation and its stockholders, and authorizing the appropriate officers of the Corporation to solicit the consent of the stockholders therefor, which resolutions setting forth the proposed amendments are as follows:

**RESOLVED**, that the first paragraph of ARTICLE IV of the Fourth Amended and Restated Certificate of Incorporation, as amended, is hereby replaced in its entirety to read as follows:

"The total number of shares of capital stock which the Corporation shall have authority to issue is 460,000,000 of which (i) four hundred and fifty million (450,000,000) shares shall be a class designated as common stock, par value $0.001 per share (the "Common Stock"), and (ii) ten million (10,000,000) shares shall be a class designated as undesignated preferred stock, par value $0.001 per share (the "Undesignated Preferred Stock")."

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**3.**That the foregoing amendment was approved by the holders of the requisite number of shares of the Corporation in accordance with Section 228 of the General Corporation Law.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**4.**That said amendment has been duly adopted in accordance with Section 242 of the General Corporation Law.

**In Witness Whereof**, this Certificate of Second Amendment has been executed by a duly authorized officer of the Corporation on this 9th day of June, 2026.

---

| | |
|:---|:---|
| &nbsp;&nbsp;By: | &nbsp;&nbsp;/s/ Sanjiv K. Patel |

---

&nbsp;&nbsp;&nbsp;&nbsp;Name: Sanjiv K. Patel

&nbsp;&nbsp;&nbsp;&nbsp;Title: President and Chief Executive Officer

------